Boston Scientific hired Ian Meredith, PhD, as executive vice president and global chief medical officer.
Meredith, a cardiologist, will begin his duties in January 2017 and succeed Keith Dawkins, MD, who has been the company’s chief medical officer since January 2012. Boston Scientific announced the moves in an Oct. 10 news release.
Meredith is a professor at Australia's Monash University, director of MonashHeart and Monash Health and executive director of the Monash cardiovascular research center in Melbourne, Australia. He has performed more than 10,000 invasive cardiac and coronary procedures, according to a news release.
Meredith has also been chief or principal investigator on 30 international, multicenter trials, including the Boston Scientific Lotus Valve Reprise research program.
In August, Boston Scientific voluntarily recalled certain lots of its Lotus Valve System, which is used in transcatheter aortic valve replacements. The system is not yet FDA-approved.
“Ian is one of the world’s leading cardiac device clinical investigators and he has been an advisor to Boston Scientific for many years,” Boston Scientific CEO and chairman Mike Mahoney said in a news release. “His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role. We are delighted that he will be joining our team.”